HomeAMGN • NASDAQ
Amgen Inc
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 9.18B | 9.43% |
Operating expense | 3.50B | 12.82% |
Net income | 1.43B | 91.96% |
Net profit margin | 15.60 | 75.48% |
Earnings per share | 6.02 | 21.13% |
EBITDA | 4.35B | 5.79% |
Effective tax rate | 8.67% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 8.03B | -13.69% |
Total assets | 87.90B | -3.31% |
Total liabilities | 80.47B | -5.31% |
Total equity | 7.43B | — |
Shares outstanding | 538.36M | — |
Price to book | 20.70 | — |
Return on assets | 8.47% | — |
Return on capital | 11.81% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 1.43B | 91.96% |
Cash from operations | 2.28B | -7.28% |
Cash from investing | -389.00M | -79.26% |
Cash from financing | -2.67B | -0.91% |
Net change in cash | -782.00M | -92.14% |
Free cash flow | 220.75M | -92.64% |
Previous close
$285.61
Day range
$285.16 - $288.30
Year range
$253.30 - $339.17
Market cap
156.17B USD
Avg Volume
1.95M
P/E ratio
23.53
Dividend yield
3.31%
Primary exchange
NASDAQ
About
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia
Founded
Apr 8, 1980
Headquarters
Website
Employees
28,000
